Nimotuzumab is an EGFR monoclonal antibody that has been approved as an orphan drug for the treatment of glioma and head and neck squamous cell carcinomas and in the process of clinical trials for other solid tumors including NSCLC [41, 42]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.